Alan Pollack, MD, PhD

Chair and Professor of Radiation Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center

[Alan Pollack, MD, PhD @_APollack]

@HimanshuNagarMD @Rad_Nation @PBlanchardMD @TheLancet Not enough bandwidth for fourth arm (huge numbers of pts). Decision based on 94-13. Ramey et al Eur Urol 2018 sheds some light on that arm. There are no solid data on upfront PLNRT vs salvage PLNRT, but we know the benefit of upfront intensification. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@HimanshuNagarMD @Rad_Nation @PBlanchardMD @TheLancet Good point. 71% in Arm 1 is at 5 yr and FFP continues to drop. Incremental benefit was observed at low and high PSA levels. Other prognostic factors and comorbidities may influence the decision. Intensification upfront reduces the chance of lifelong ADT later. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@Sushilberiwal @Rad_Nation @PBlanchardMD @HimanshuNagarMD @TheLancet Great question because we all know that one size does not fit all. The PSA >0.35 is one criterion, but consider PLNRT with lower PSAs and other adverse factors such as negative margins, high grade, SVI, no or few LNs sampled, High Decipher score. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@HinaSaeedMD @Rad_Nation @PBlanchardMD @HimanshuNagarMD @TheLancet @DrChowdharyMD @sophia_kamran There was no significant difference (supplementary Figure), but it was a subset analysis with reduced numbers. 6 months trended higher, but p=0.3. If you are going to use Orgovyx, I recommend 6 months because of the fast recovery. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@Rad_Nation @PBlanchardMD @HimanshuNagarMD @TheLancet 3) All patients benefitted from short term ADT
4) Those with PSAs above the median (0.35) benefitted most from PLNRT.

Question: Should we wait for patients to declare themselves and then give PLNRT?
Answer: No (to be continued) #Radon #JC

[Alan Pollack, MD, PhD @_APollack]

@Rad_Nation @PBlanchardMD @HimanshuNagarMD @TheLancet Other points:
1) Adding PLNRT to PBRT+ADT resulted in a significant benefit by the primary endpoint 5 yr FFP.
2) Forest plots in Fig 3 at 8 yr show less of a benefit for Group 3 vs 2; although arm 3 had the lowest DM and CSD rates at only median FU 8.2 yr. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@Rad_Nation @the_lancet Doubling time inclusion nearly killed the study. It required 3 PSAs at 2 mo intervals (anxious pts). Also, short PSADTs were excluded (CTEP requirement), which Trock et al showed in JAMA using Hopkins data was a mistake. With exclusion accrual skyrocketed. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@Rad_Nation @the_lancet Also on Endpoints: We included a more standard biochemical failure cutpoint of 0.4 and in an ad hoc analysis second salvage ADT (see Fig 4), aside from local fialure, DM, CSM, and OS. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@Rad_Nation @the_lancet Endpoints: Primary endpoint was 5yr FFP mainly based on nadir+2. See Appendix in the paper for justification. Correlated with clinical failure. Included death from any cause (standard CTEP requirement). With longer FU, increased arm convergence expected. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@Rad_Nation @the_lancet Volumes: established RTOG/NRG volumes based on publications by Michalski et al and Lawton et al. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@Rad_Nation @IanJPereira @MonaArbabMD @SaraBelPonMD @AmishiBajajMD @HinaSaeedMD @ChaurasiaMD @RadOncDoc_Niema @subatomicdoc While SPPORT was incubating, the POP-RT trial provided further support for PLLNRT in the primary treatment setting. Also, fluciclovine (Axumin) and PSMA PET have demonstrated the pelvic and para-aortic LN recurrences are much greater than expected. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@Rad_Nation @IanJPereira @MonaArbabMD @SaraBelPonMD @AmishiBajajMD @HinaSaeedMD @ChaurasiaMD @RadOncDoc_Niema @subatomicdoc Concerning the treatment of the pelvic LNs, prior to SPPORT there were retrospective studies supporting a benefit, but no randomized studies in the salvage setting. SPPORT was designed based on early RTOG 94-13 results for primary prostate treatment. #radonc #jc

[Alan Pollack, MD, PhD @_APollack]

@Rad_Nation @TheLancet Yes, GETUG AFU-16 and RTOG 9601 are the main complimentary randomized trials to the SPPORT trial. The GETUG trial is the most comparable, because both SPPORT and GETUG used short term ADT. All three trials showed outcome benefits from the addition of ADT to prostate bed RT.

[Alan Pollack, MD, PhD @_APollack]

@Rad_Nation @TheLancet Yes, GETUG AFU-16 and RTOG 9601 are the main complimentary randomized trials to the SPPORT trial. The GETUG trial is the most comparable, because both SPPORT and GETUG used short term ADT. All three trials showed outcome benefits from the addition of ADT to prostate bed RT.